BGB-283, a novel RAF kinase and EGFR inhibitor, displays potent antitumor activity in BRAF-mutated colorectal cancers

Molecular Cancer Therapeutics

Volumn 14, Issue 10, 2015, Pages 2187-2197

  Tang, Zhiyu ^a   Yuan, Xi ^a   Du, Rong ^a   Cheung, Shing Hu ^a   Zhang, Guoliang ^a   Wei, Jing ^a   Zhao, Yuan ^a   Feng, Yingcai ^a   Peng, Hao ^a   Zhang, Yi ^a   Du, Yunguang ^a   Hu, Xiaoxia ^a   Gong, Wenfeng ^a   Liu, Yong ^a   Gao, Yajuan ^a   Liu, Ye ^a   Hao, Rui ^a   Li, Shengjian ^a   Wang, Shaohui ^a   Ji, Jiafu ^b   Zhang, Lianhai ^b   Li, Shuangxi ^b   Sutton, David ^a   Wei, Min ^a   Zhou, Changyou ^a   Wang, Lai ^a   Luo, Lusong ^a   more..

^a BeiGene   (China)

^b Department of Biochemistry and Molecular BiologyCancer Hospital of Peking University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BGB 283; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; BGB-283; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NAPHTHYRIDINE DERIVATIVE; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; FEMALE; GENE MUTATION; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMICAL STRUCTURE; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVE SITE; GENETICS; HUMAN; METABOLISM; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; MODELS, MOLECULAR; NAPHTHYRIDINES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS B-RAF; RAF KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946708743     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0262     Document Type: Article

References (32)

1. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002;12:9-18.
2. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26: 3291-310.
3. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47.
4. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009;27: 9000.
5. Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380: 358-65.
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
7. English DR, Young JP, Simpson JA, Jenkins MA, Southey MC, Walsh MD, et al. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev 2008;17:1774-80.
8. Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R, et al. Distinct clinical and pathological features are associated with the BRAFT1799A (V600E) mutation in primary melanoma. J Invest Dermatol 2006;127: 900-5.
9. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-46.
10. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58:90-6.
11. Vaughn CP, ZoBell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011;50:307-12.
12. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
13. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAFV599E in human melanoma abrogates transformation. Cancer Res 2003;63:5198-202.
14. Conner SR, Scott G, Aplin AE. Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. J Biol Chem 2003;278: 34548-54.
15. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
16. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
17. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brainmetastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893-901.
18. Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013;14:e11-8.
19. Anforth RM, Blumetti TCMP, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012;167:1153-60.
20. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
21. Kopetz S, Desai J, Chan E, Hecht J, O'dwyer P, Lee R, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010;28:3534.
22. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012;2:227-35.
23. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
24. Li L, Cheung S-h, Evans EL, Shaw PE. Modulation of gene expression and tumor cell growth by redox modification of STAT3. Cancer Res 2010;70:8222-32.
25. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutantmelanoma. Nature 2010;467:596-9.
26. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5.
27. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140: 209-21.
28. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30.
29. Palacios R, Steinmetz M. IL3-dependent mouse clones that express B-220 surface antigen, contain ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 1985;41:727-34.
30. Jiang J, Greulich H, Jänne PA, Sellers WR, Meyerson M, Griffin JD. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinibsensitive cell cycle progression. Cancer Res 2005;65:8968-74.
31. He M, Capelletti M, Nafa K, Yun CH, Arcila ME, Miller VA, et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res 2012;18:1790-7.
32. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012;72:779-89.